Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$118 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.3
Industry P/E
--
EV/EBITDA
-2.1
Div. Yield
0 %
Debt to Equity
--
Book Value
$1.8
EPS
$-1.2
Face value
--
Shares outstanding
35,941,195
CFO
$-115.08 Mln
EBITDA
$-147.04 Mln
Net Profit
$-146.91 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
| 186.8 | 197.3 | 186.8 | 137.0 | -30.8 | -- | -- |
|
BSE Sensex*
| -13.8 | -8.8 | -14.6 | -3.2 | 6.9 | 8.2 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
| -17.4 | -93.1 | 115.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
3.3 | 117.5 | 0.0 | -35.2 | -- | -52.1 | -- | 2.3 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 64.5 | 7,640.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.2 | 156.5 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for... patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California. Read more
Co-founder & Chairman of the Board
Mr. Joseph S. Zakrzewski
Co-founder & Chairman of the Board
Mr. Joseph S. Zakrzewski
Headquarters
Menlo Park, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of AN2 Therapeutics Inc (ANTX) is $3.27 (NASDAQ) as of 02-Apr-2026 16:00 EDT. AN2 Therapeutics Inc (ANTX) has given a return of -30.8% in the last 3 years.
Since, TTM earnings of AN2 Therapeutics Inc (ANTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.97
|
0.64
|
|
2024
|
-0.81
|
0.51
|
|
2023
|
-7.60
|
3.94
|
|
2022
|
-3.45
|
1.50
|
|
2021
|
--
|
--
|
The 52-week high and low of AN2 Therapeutics Inc (ANTX) are Rs 6.91 and Rs 1.00 as of 06-Apr-2026.
AN2 Therapeutics Inc (ANTX) has a market capitalisation of $ 118 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in AN2 Therapeutics Inc (ANTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.18
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.